Transmembrane Helix 11 of Multidrug Resistance Protein 1 (MRP1/ABCC1): Identification of Polar Amino Acids Important for Substrate Specificity and Binding of ATP at Nucleotide Binding Domain 1
- 1 July 2004
- journal article
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 43 (29) , 9413-9425
- https://doi.org/10.1021/bi0495230
Abstract
Human multidrug resistance protein 1 (MRP1) is an ATP binding cassette (ABC) transporter that confers resistance to many natural product chemotherapeutic agents and can transport structurally diverse conjugated organic anions. MRP1 has three polytopic transmembrane domains (TMDs) and a total of 17 TM helices. Photolabeling and mutagenesis studies of MRP1 indicate that TM11, the last helix in the second TMD, may form part of the protein's substrate binding pocket. We have demonstrated that certain polar residues within a number of TM helices, including Arg593 in TM11, are determinants of MRP1 substrate specificity or overall activity. We have now extended these analyses to assess the functional consequences of mutating the remaining seven polar residues within and near TM11. Mutations Q580A, T581A, and S585A in the predicted outer leaflet region of the helix had no detectable effect on function, while mutation of three residues close to the membrane/cytoplasm interface altered substrate specificity. Two of these mutations affected only drug resistance. N597A increased and decreased resistance to vincristine and VP-16, respectively, while S605A decreased resistance to vincristine, VP-16 and doxorubicin. The third, S604A, selectively increased 17β-estradiol 17-(β-d-glucuronide) (E217βG) transport. In contrast, elimination of the polar character of the residue at position 590 (Asn in the wild-type protein) uniformly impaired the ability of MRP1 to transport potential physiological substrates and to confer resistance to three different classes of natural product drugs. Kinetic and photolabeling studies revealed that mutation N590A not only decreased the affinity of MRP1 for cysteinyl leukotriene 4 (LTC4) but also substantially reduced the binding of ATP to nucleotide binding domain 1 (NBD1). Thus, polar interactions involving residues in TM11 influence not only the substrate specificity of MRP1 but also an early step in the proposed catalytic cycle of the protein.Keywords
This publication has 17 references indexed in Scilit:
- Identification of a region of strong discrimination in the pore of CFTRAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2001
- Two new genes from the human ATP-binding cassette transporter superfamily, ABCC11 and ABCC12, tandemly duplicated on chromosome 16q12Gene, 2001
- Transport of the β-O-Glucuronide Conjugate of the Tobacco-specific Carcinogen 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by the Multidrug Resistance Protein 1 (MRP1)Published by Elsevier ,2001
- Major Photoaffinity Drug Binding Sites in Multidrug Resistance Protein 1 (MRP1) Are within Transmembrane Domains 10–11 and 16–17Journal of Biological Chemistry, 2001
- A Family of Drug Transporters: the Multidrug Resistance-Associated ProteinsJNCI Journal of the National Cancer Institute, 2000
- ATP‐ and glutathione‐dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1British Journal of Pharmacology, 1999
- Topology Mapping of the Amino-terminal Half of Multidrug Resistance-associated Protein by Epitope Insertion and ImmunofluorescenceJournal of Biological Chemistry, 1997
- Membrane Topology of the Multidrug Resistance Protein (MRP)Journal of Biological Chemistry, 1997
- Membrane Topology and Glycosylation of the Human Multidrug Resistance-associated ProteinJournal of Biological Chemistry, 1996
- ATP-dependent glutathione disulphide transport mediated by the MRP gene-encoded conjugate export pumpBiochemical Journal, 1996